Elucidata Closes $16M Series A to Advance Biotech AI Platform

Elucidata has secured $16,000,000 in its Series A funding round. The investment was led by Eight Roads and F-Prime, with continued participation from existing investors Hyperplane and IvyCap. This capital infusion supports Elucidata's mission to streamline data processing for life sciences research. Elucidata is recognized for its data harmonization platform, Polly, which empowers scientists by making multi-modal biomedical data Machine Learning ready. The platform addresses a significant challenge in early R&D, precision diagnostics, and translational biomarker teams, where scientists typically spend a large portion of their time on data wrangling. Polly consistently processes, curates, and ensures the quality of diverse biomedical datasets, allowing researchers to dedicate more time to their core scientific endeavors. Polly transforms complex, multi-source data, including Omics, Assay, Real World Data, Clinical & EHR Data, and CRO data, into a Unified Data Model. Leveraging LLM-powered curation and human-in-the-loop verification, the platform achieves high accuracy and significantly accelerates time to analysis. Currently, Polly facilitates critical use cases such as patient stratification, biomarker discovery, target identification and validation, and data management for over 35 premier biopharma companies and research labs, including Pfizer and Janssen Pharmaceuticals. The newly secured funding will be instrumental in Elucidata's continued growth and development. The company plans to use the capital to expand its platform capabilities, enhance its data harmonization offerings, and scale its operations to serve a broader range of life sciences organizations. This investment underscores investor confidence in Elucidata's technology and its potential to revolutionize data utilization in biomedical research. With this funding, Elucidata is poised to further accelerate its innovation pipeline and strengthen its market presence, continuing its commitment to empowering scientists and advancing the pace of scientific discovery in the life sciences field.